CN108025000A - 角膜真菌病的预防或治疗剂 - Google Patents

角膜真菌病的预防或治疗剂 Download PDF

Info

Publication number
CN108025000A
CN108025000A CN201680054195.5A CN201680054195A CN108025000A CN 108025000 A CN108025000 A CN 108025000A CN 201680054195 A CN201680054195 A CN 201680054195A CN 108025000 A CN108025000 A CN 108025000A
Authority
CN
China
Prior art keywords
rapamycin
polyethylene glycol
therapeutic agent
prevention
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680054195.5A
Other languages
English (en)
Chinese (zh)
Inventor
张金忠
景山正明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of CN108025000A publication Critical patent/CN108025000A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201680054195.5A 2015-09-18 2016-09-13 角膜真菌病的预防或治疗剂 Pending CN108025000A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562220847P 2015-09-18 2015-09-18
US62/220,847 2015-09-18
PCT/JP2016/077014 WO2017047597A1 (ja) 2015-09-18 2016-09-13 角膜真菌症の予防または治療剤

Publications (1)

Publication Number Publication Date
CN108025000A true CN108025000A (zh) 2018-05-11

Family

ID=58288799

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680054195.5A Pending CN108025000A (zh) 2015-09-18 2016-09-13 角膜真菌病的预防或治疗剂

Country Status (13)

Country Link
US (1) US10166217B2 (https=)
EP (1) EP3351244A4 (https=)
JP (1) JP6639364B2 (https=)
KR (1) KR20180053340A (https=)
CN (1) CN108025000A (https=)
BR (1) BR112018005305A2 (https=)
HK (2) HK1256969A1 (https=)
MX (1) MX393608B (https=)
MY (1) MY183906A (https=)
PH (1) PH12018500579A1 (https=)
SG (1) SG11201802091RA (https=)
TW (1) TWI721015B (https=)
WO (1) WO2017047597A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112957321B (zh) * 2021-03-04 2022-08-05 青岛大学附属医院 一种氧化硫酸软骨素改性的那他霉素滴眼液及其制备方法
CN114568490B (zh) * 2022-04-01 2023-12-19 眉山职业技术学院(眉山技师学院) 雷帕霉素在抑制柑橘青霉菌生长中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101137370A (zh) * 2005-02-09 2008-03-05 马库赛特公司 用于治疗疾病或病症的液体制剂
CN101827523A (zh) * 2007-08-16 2010-09-08 马库赛特公司 用于治疗眼部疾病或病症的制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4974903B2 (ja) 2005-02-09 2012-07-11 参天製薬株式会社 疾患または状態を処置するための液体処方物
PL2001466T3 (pl) 2006-03-23 2016-06-30 Santen Pharmaceutical Co Ltd Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101137370A (zh) * 2005-02-09 2008-03-05 马库赛特公司 用于治疗疾病或病症的液体制剂
CN101827523A (zh) * 2007-08-16 2010-09-08 马库赛特公司 用于治疗眼部疾病或病症的制剂

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
M LIVIA BAJENARU等: "Preclinical evaluation of new therapies in a fungal keratitis rat model", 《ARVO ANNUAL MEETING ABSTRACT》 *
廖美琳、周允中著: "《肺癌 第3版》", 31 May 2012, 上海科学技术出版社 *
朱秀安主编: "《眼科疑难病》", 31 August 2009, 科学技术文献出版社 *

Also Published As

Publication number Publication date
KR20180053340A (ko) 2018-05-21
HK1256969A1 (en) 2019-10-04
SG11201802091RA (en) 2018-04-27
MY183906A (en) 2021-03-17
BR112018005305A2 (pt) 2018-10-09
MX393608B (es) 2025-03-24
US10166217B2 (en) 2019-01-01
HK1253545A1 (zh) 2019-06-21
TW201717943A (zh) 2017-06-01
PH12018500579A1 (en) 2018-09-10
US20180271841A1 (en) 2018-09-27
JP2017057199A (ja) 2017-03-23
JP6639364B2 (ja) 2020-02-05
TWI721015B (zh) 2021-03-11
WO2017047597A1 (ja) 2017-03-23
MX2018003381A (es) 2018-08-15
EP3351244A1 (en) 2018-07-25
EP3351244A4 (en) 2019-05-01

Similar Documents

Publication Publication Date Title
US11439652B2 (en) Ophthalmic aqueous composition
US11819533B2 (en) Compositions and methods for the treatment of fungal infections
US11612590B2 (en) Therapeutic agent for meibomian dysfunction
US20240091221A1 (en) Parenteral formulations and uses thereof
WO2016171152A1 (ja) 角膜障害の治療剤、改善剤または予防剤
AU2021230529B2 (en) Use of compounds in the treatment of fungal infections
US20170304451A1 (en) Parenteral compositions of bendamustine
TW201518291A (zh) 含聚乙二醇之組成物
TWI721015B (zh) 角膜真菌症之預防或治療劑
AU2019328599B2 (en) Compounds and methods for treating fungal infections
JP3502574B2 (ja) 眼感染症治療用眼軟膏剤
EP3369422A1 (en) External preparation
US9987368B2 (en) Pharmaceutical composition comprising polypeptide
US11672798B2 (en) Ciprofloxacin ophthalmic topical composition for treating ocular disease
TW201906597A (zh) 含有水溶性黏稠化劑之醫藥組合物
CN120282788A (zh) 提高组织迁移性及防腐效力的含有依匹斯汀的水性组合物
HK1238174A1 (en) Ophthalmic aqueous composition
HK1235711A1 (en) Ophthalmic aqueous composition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1253545

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20180511

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1253545

Country of ref document: HK